PRISM MarketView launched the PRISM PetCare Index to track publicly traded companies driving growth in the global pet care sector, projected to exceed $350 billion. The index includes companies advancing veterinary services, pet pharmaceuticals, insurance, diagnostics, and premium nutrition. Key companies highlighted include Elanco Animal Health, Chewy, and Trupanion, which are positioned to benefit from increasing consumer spending on pet healthcare, preventative services, and subscription-based offerings.

Zoetis is set to report Q4 2025 earnings on Feb. 12 after disappointing guidance last quarter caused an 11% stock decline. While the company has beaten earnings in four consecutive quarters and lowered expectations could set up positive surprises, investors remain concerned about persistent macro headwinds affecting its livestock business and osteoarthritis treatments. The analyst recommends long-term investors wait until after earnings to enter a position, as further downside risk exists if guidance disappoints again.

The global canine glucosamine supplement market is experiencing rapid growth, expanding from USD 236.44 million in 2025 to USD 257.55 million in 2026, with a projected CAGR of 7.27% through 2032, reaching USD 386.54 million. Market growth is driven by increased pet ownership, higher consumer spending on veterinary wellness, product innovation in formats like chewables and liquids, and omnichannel distribution strategies. Key opportunities include palatability improvements, multi-ingredient formulations, and age-specific product targeting.

The global canine vaccines market is projected to grow from USD 2.05 billion in 2025 to USD 3.45 billion by 2033, with a CAGR of 6.79%. Growth is driven by rising pet ownership, increased awareness of preventive animal healthcare, and higher veterinary spending. Core vaccines and rabies vaccines lead by market share, while combination vaccines and Lyme disease vaccines show the fastest growth. North America dominates with 36.5% market share, while Asia Pacific is expected to grow fastest at 8.22% CAGR.

The global diesel generator market is projected to grow at a CAGR of 5.28% from 2026 to 2032, reaching USD 27.42 billion by 2032 from USD 18.17 billion in 2024. Growth is driven by industrialization, infrastructure development, rising power outages, and data center expansion. However, the market faces headwinds from stringent environmental regulations, high operational costs, and the shift toward renewable energy solutions.

Virbac has acquired a specialized liquid medication for feline hyperthyroidism from Norbrook for around £100 million. The product, currently generating €14 million in revenue, will be distributed under the Thyronorm and Felanorm brands across multiple markets.

Virbac has acquired an innovative drug from Norbrook to treat feline hyperthyroidism, valued at £100 million. The product will be distributed under Thyronorm and Felanorm brands across multiple countries, targeting a growing market of senior cats with this common endocrine disease.

Elanco Animal Health outlined a strategic plan for sustainable growth, focusing on innovation, portfolio expansion, and productivity. The company expects mid-single-digit organic revenue growth, increased R&D investments, and significant cost savings through its Ascend productivity initiative.

KeyBanc Capital Markets initiated coverage on Elanco Animal Health, rating it Overweight with a $27 price target. The analyst believes the company's innovative pet care products and improving financial metrics make the stock undervalued.

The global companion animal health market is projected to grow from USD 25.28 billion in 2024 to USD 61.74 billion by 2034, driven by rising pet ownership, pet humanization trends, and advances in veterinary technologies.

The global pet cancer therapeutics market is projected to grow from $493 million in 2025 to $1.15 billion by 2034, driven by increasing pet cancer awareness, advanced veterinary treatments, and growing pet humanization trends.

The veterinary oncology market is projected to grow from $1.84 billion in 2025 to $3.55 billion by 2030, driven by technological advances, rising pet ownership, and increasing demand for advanced cancer treatments in veterinary medicine.